IL6 and cancer: Inflammatory markers and fatigue are closely related during the treatment of cancer patients, with high levels of interleukin 6 (IL-6), interleukin 1 (IL-1), and tumor necrosis factor-alpha positively correlating with the degree of fatigue after chemotherapy in cancer patients [46].